Need professional-grade analysis? Visit stockanalysis.com
$160.33M
N/A
N/A
N/A
Tiziana Life Sciences Ltd (TLSA) trades on United States in USD. The company is classified in the Healthcare sector under the Pharmaceutical Preparations industry. The stock currently trades at $1.23, down 0.81% from the previous close.
Over the past year, TLSA has traded between a low of $1.15 and a high of $2.50. The stock has lost 6.1% over this period. It is currently 50.8% below its 52-week high.
Tiziana Life Sciences Ltd has a market capitalization of $160.33M.
Tiziana Life Sciences Ltd, a biotechnology company, engages in the development of transformative therapies for neurodegenerative and lung diseases in the United States. The company's lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for use in the treatment of Crohn's, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases. It is also developing TZLS-501, a fully human mAb targeting the IL-6 receptor for use in the treatment of inflammatory and oncology indications. Tiziana Life Sciences Ltd was incorporated in 1998 and is headquartered in London, the United Kingdom.
Side-by-side comparison against top Healthcare peers.